Silgan Holdings Inc. (SLGN) Earnings Call Transcript & Summary

October 29, 2026

New York Stock Exchange US Materials Containers and Packaging earnings 54 min

Earnings Call Speaker Segments

Alex Hutter

executive
#1

Thank you, and good morning. On today's call with me are Adam Greenlee, our President and CEO, and Shawn Fabry, our EVP and CFO. Before we get started today, we want to be clear that some of the statements we make on this conference call may be forward-looking statements. Such forward-looking statements reflect management's expectations and beliefs about future events that could affect the company, and as a result they carry a number of uncertainties and risks, including but not limited to the ones described in the company's annual report on Form 10-K for 2025 and other filings with the Securities and Exchange Commission. Accordingly, the company's actual results of operations or financial condition could differ materially from those expressed or implied in those forward-looking statements. In addition, commentary on today's call may reference certain non-GAAP financial metrics, including adjusted EBIT, adjusted EBITDA, free cash flow, and adjusted net income per diluted share or adjusted EPS. Reconciliations of these metrics, which should not be considered substitutes for similar GAAP metrics, are available in today's press release and under the non-GAAP financial information portion of the investor relations section of our website at silganholdings.com. With that, let me turn it over to Adam.

Adam Greenlee

executive
#2

We appreciate that introduction, Alex, and we'd like to extend a warm welcome to everyone joining Silgan's third quarter earnings call. During our conversation last week, we covered a transformative portfolio acceleration as Silgan embarks on the next stage of our value creation journey through the proposed acquisition of Trivium, which establishes two exceptional packaging companies in Silgan MCC and Silgan DS. We're pleased to return today to discuss yet another strong quarter of financial performance across our business and our continued progress along the company's strategic direction. The objectives we set for 2026 are straightforward: continue executing our strategic growth initiatives, deliver earnings growth no matter how our end markets perform, and invest in the future growth of the business. So far this year, fragrance dispensing products have grown at a mid-single-digit rate, wet pet food and Metal Containers also posted mid-single-digit growth, and interest in our healthcare pharma dispensing products has been substantial and keeps building. Even with consumer demand conditions that have been tougher and considerable inflation in raw materials and other costs over the course of the year, we have twice lifted the midpoint of our full-year adjusted EPS guidance. Our teams make me proud — their unrelenting emphasis on execution and their dedication to meeting the distinctive needs of our customers are what let Silgan remain the best at what we do. I think the company is in a strong position to meet what we've promised shareholders as Silgan enters this next chapter in 2027. Looking at Q3, our operations did well, and our people successfully navigated difficult consumer circumstances, ongoing cost pressures, and unfavorable currency effects. Silgan posted record adjusted EPS at the top of the range we had projected, and once again, the strength and agility of our teams and the success of our strategic growth initiatives delivered strong financial results. In Dispensing and Specialty Closures, we posted yet another solid quarter, with mid-single-digit growth for our premium fragrance offerings. Our prescription pharma dispensing products keep picking up momentum in the market, posting a double-digit percentage increase in North America. Our teams remain leaders in the market, since our best-in-class approach to innovation, investment and growth, along with our customer partnership model, sets us apart from competitors and fuels volume growth ahead of our end markets. Although cost inflation was still a headwind during Q3, and the pass-through mechanisms in this business typically lag a bit longer than at our other businesses, we managed to put actions in place in the third and fourth quarters that recover cost increases and will help offset a substantial portion of the impact. Growth was reported in our Metal Containers segment for fruit and vegetable as well as wet pet food products. Even with volumes in soup markets coming in softer than expected, adjusted EBIT was up 10% year-over-year. As demand and production in the fruit and vegetable market return to a more normal rhythm following several turbulent years, our team's steadfast focus on cost efficiency continues to flow through to the bottom line. Even with raw material prices continuing to swing, higher shipping costs, and softer demand patterns in the markets this unit supplies, our people delivered another quarter of strong performance in Custom Containers. We shipped lower volumes than a year ago—due in part to walking away from lower-margin work in support of last year's cost-cutting programs—but adjusted EBIT for this business still set a record for another quarter. Those third-quarter numbers once more demonstrate the power of our strategic growth efforts, the durability of our operations when consumer demand weakens, and our ability to grow faster than rivals and the markets we serve by leveraging our unique commercial partnerships. Looking ahead to Q4, our confidence is high that we'll hit the upgraded financial targets we've set for both the back half and the entire year, despite fresh difficulties that have cropped up since we last reported. Throughout this year we've consistently noted that our 2026 planning baked in greater uncertainty along the way. A Middle East conflict wasn't something we anticipated, nor were resin costs rising beyond 50%, softness in Brazil, or numerous other obstacles that arose and were addressed over the course of the year—and yet the fundamental resilience of our operations and the rigorous execution by our teams enabled us to lift our financial expectations for the year. Given a tough macroeconomic environment, we see this performance as clearly distinguished relative to our competitive landscape. Our unique lineup of everyday consumer products across the markets we serve—combined with industry-leading innovation, our particular approach to deploying capital, long-standing customer relationships, and a low-cost worldwide manufacturing base—continues to differentiate Silgan in the marketplace and positions us strongly to keep delivering superior results through a variety of economic environments. Fulfilling our 2026 financial commitments remains our top near-term focus. Although we're starting an exciting new chapter at Silgan, fundamentally nothing has shifted in our thinking about strategic growth efforts, end market expansion, capital deployment, business strategy, customer partnerships, or any of the company's foundational elements. We actually think that with the structure we've laid out, Silgan DS and Silgan MCC will each be in a stronger position to chase their own strategic priorities and create shareholder value; since the Trivium deal is expected to close in mid-2027, during the first half of the year we'll concentrate on keeping these strategic initiatives on track, getting ready for integration, and setting both businesses up to succeed once the new operating structure is in place. This deal will probably also involve a certain amount of added investment across both organizations so the businesses are properly positioned to succeed over the long term, but even so, we anticipate 2027 to deliver yet another year of growth in organic earnings and free cash flow. On that note, Shawn is going to walk you through the quarter's financials as well as what we're projecting for the fourth quarter and for the full year of 2026.

Shawn Fabry

executive
#3

Thank you, Adam. As Adam pointed out, we delivered yet another quarter of solid results in Q3 of 2026, with adjusted EPS landing at the high end of the range we had projected, driven by robust operational EBIT performance across every segment plus favorable interest expense, partly offset by an adjusted tax rate that was higher than in the same quarter last year. Net sales came to roughly $2 billion, up 2% versus the year-ago period, reflecting the pass-through of elevated raw material and other costs in each of our segments. Total adjusted EBIT for the quarter reached $235 million, 6% above the prior year, chiefly because of stronger adjusted EBIT in our Metal Containers business. Adjusted EPS of $1.31 rose 7% compared with the prior year period, thanks to higher adjusted EBIT and reduced interest expense, partly offset by a higher adjusted tax rate. Now looking at our segments: third quarter sales in Dispensing and Specialty Closures grew 1% over the prior year, mainly from passing through higher raw material and other costs. Volumes for the quarter were flat year-over-year, as strong growth in fragrance and prescription pharma dispensing products was offset by lower volumes for food and beverage products. Third quarter adjusted EBIT for Dispensing and Specialty Closures fell $2 million relative to the prior year quarter, largely because of unrecovered inflation in the current year quarter that we anticipate recouping via pricing actions in the market over the coming couple of quarters. In Metal Containers, sales rose 1% versus the prior year quarter, driven by the contractual pass-through of higher raw material and other manufacturing costs, principally steel and aluminum, partly offset by volumes that were 4% lower. As Adam mentioned, higher volumes for fruit and vegetable and wet pet food products were offset by weaker demand for soup products in the current year quarter. Metal Containers adjusted EBIT came in $9 million above prior year levels, as a more normalized volume cadence in 2026 and a stable footprint exiting our multi-year cost reduction initiative produced more streamlined operations and favorable price over cost performance; in Custom Containers, results were largely in line with our expectations, with sales up 4% compared to the prior year quarter due to the pass-through of higher raw material and other cost inflation, partly offset by an 8% decline in volumes. As expected, volumes were affected by the exit of lower margin business tied to the planned footprint optimization in the prior year. Custom Containers adjusted EBIT exceeded prior year levels on favorable price over cost, including mix, which includes the cost savings from the footprint optimization that drove lower volumes. Corporate expense, excluding costs for announced acquisitions, was roughly $6 million below the prior year level, partly due to the reversal of corporate development costs associated with the recently announced acquisition of Trivium. Now, moving to what we expect in Q4 of 2026: our projected adjusted earnings fall between $0.76 and $0.86 for each diluted share, versus adjusted EPS of $0.67 during the same period last year. At the midpoint, that guidance reflects adjusted EBIT rising roughly $10 million-$15 million compared with a year earlier, interest expense of $45 million-$50 million, and a tax rate near 25%-26%. In Q4, volumes across every segment should be similar to last year's levels; for all of 2026, as Adam mentioned, we're raising our adjusted EPS estimate to $3.83- $3.93, which is a 4% gain at the midpoint versus $3.72 in 2025. That figure incorporates adjusted EBIT growth in the low single-digit percentage range, adjusted corporate expense near $45 million-$50 million, interest expense of about $185 million, and a tax rate expected at 25%-26%; volumes for 2026 are now anticipated to match the prior year period across all three segments. Given our present earnings forecast for 2026, we are reaffirming our free cash flow estimate of roughly $450 million, including CapEx of approximately $310 million. With that said, let's begin the question and answer portion. Jess, could you please give the instructions for the Q&A session?

Ghansham Panjabi

analyst
#4

Yeah. Thanks, operator. Morning, everyone. Adam, could you perhaps go into more detail on what you said regarding the consumer packaging business and the softer consumer and so forth? Clearly, conditions have been sluggish for nearly several years now; so what precisely has gotten incrementally worse? What are your customers telling you about their strategy to counter some of this as we look ahead to 2027?

Adam Greenlee

executive
#5

Yeah. Morning, Ghansham. I’d say it’s a continuation of what we’ve been observing, right? So, certainly there are pockets in our portfolio that have shown considerable strength, right? Be it mid-single digit growth in our wet pet food segment. We mentioned, once more, outstanding results in our fragrance products and now a prescription pharma business that is accelerating quickly and growing too. We have consumers mainly, kind of, in the food and beverage market, perhaps a bit of home care and lawn and garden I’d include there too, but that’s really where we’re seeing some challenged behavior from the consumer as they keep looking for ways to stretch their dollar. We’re seeing it affect that portion of our portfolio. But, I think we feel quite good about the strategic initiatives we have that are driving volume growth through other pockets of the portfolio.

Ghansham Panjabi

analyst
#6

All right, understood. Turning to the DSC segment, if you look at EBIT margins on a year-over-year basis, that marks roughly six straight quarters of margin contraction measured that way. Clearly there's a great deal happening with end markets and inflation, but how long do you figure it will reasonably take for margins to steady on that same basis? Are we talking 4Q? Is that the assumption you've built into your model right now?

Adam Greenlee

executive
#7

What I'd tell you is that 4Q should bring some normalization. Clearly, a great deal of inflation has been passed through, Ghansham, whether that's raw materials in DSC. You're coping not just with resin, but you also have the metal closures piece there, and steel inflation has been significant. So by and large, we pass those along very promptly. Some lag will exist, and part of that recovery of the other inflation will also come next year; but my view is that Q4 will show a nice recovery of the inflation. In cases where we lacked contractual pass-throughs for certain inflationary items, we've pursued aggressive pricing actions in the market to recoup those costs. You'll see that begin to flow through in Q4.

Ghansham Panjabi

analyst
#8

All right, great. Thanks very much.

George Staphos

analyst
#9

Morning, everybody. Thanks for the specifics. I'd like to build on the two subjects Ghansham brought up. When it comes to DSC, Adam, and the decent rebound you're anticipating from passing through resin costs and recovering there, should we look for earnings in DSC to rise year over year in the fourth quarter? Or is it really more of a push into 2027, since that takes a while? You did mention it takes a couple quarters to achieve that. My second question, somewhat tied to it: we had been looking for, per your guidance, low single digit growth, I believe, for both Metal Containers and Custom Containers, excluding the walkaway business, and low to mid single in DSC, I think. The consumer has clearly been pressured for some time. What exactly shifted, or to put it another way, is your volume outlook now for even volume really just a result of the pressure you're seeing in soup, and the pressure in some of the other markets you mentioned?

Adam Greenlee

executive
#10

Okay, and perhaps we can begin with your first question, George. Regarding our Q4 forecasts, or guidance, for DSC, we do expect to see organic EBIT increase year over year in Q4—I want to be very clear on that point. A portion of this comes from the catch-up recovery on inflationary pass-throughs that we discussed earlier with Ghansham. The other element is that we anticipate fragrance and beauty products will keep performing very strongly. Our prescription healthcare and pharma business is performing very well, and we think those areas will counterbalance the ongoing difficulty we're observing with consumers in certain other markets, especially food and beverage. On your second question, perhaps about Metal Containers and our Custom Containers business, and what shifted relative to our guidance: certainly, soup was an item we had not foreseen, and the straightforward explanation for you, George, is that we have one specific customer that absorbed substantial inflation during 2026—not only in relation to the food can, but also ingredients, energy, freight, and so on. They decided, and made that decision during Q3, that they would need to raise prices to recoup part of that inflation. So we believe that affected our volumes in Q3. That is now reflected in our Q4 guidance too. Consequently, we are not expecting any meaningful rebound in soup volumes during the fourth quarter. For Custom Containers, it's essentially the same situation we have been describing. It covers food and beverage. It also includes our home care and lawn and garden segments. We are simply encountering a very difficult consumer environment, with people again attempting to make their dollars go further on the spending side and altering certain behaviors. Going right back to the start, we told you—I believe we told the market—that when we entered 2026, we did not require market growth in order to achieve earnings growth and free cash flow growth in 2026; despite the difficulties we are discussing here, I think our performance has been outstanding; we exceeded the midpoint in all three quarters; we raised the year twice; we are extremely proud of what our teams have accomplished and expect more of the same in 2027.

George Staphos

analyst
#11

All right, thank you for that. You took the closing remark I had planned, but I give you credit for how you're steering things this year and still keeping your forecast intact. I have two final questions and then I'll hand it back. What's the latest in Brazil? Could you share some detail on the investment required as you integrate Trivium? Is there any way to quantify what we should factor in as we build out that model? Thanks so much.

Adam Greenlee

executive
#12

Absolutely. On Brazil, this picks up where we left off last quarter. We weren’t expecting any recovery in Q3, and to be fair, there wasn’t any recovery in Q3 — that was right in line with what we expected. By the end of the year, we should begin to see some recovery, but honestly that is more of a 2027 story. So it was a negative impact on the quarter; we were more than able to absorb it and offset it. Really, George, when you look at the products for us in Brazil, they are very mixed favorable for the company and for DSC in particular.

George Staphos

analyst
#13

Okay.

Adam Greenlee

executive
#14

When volumes in Brazil come down, that affects the mix line too.

George Staphos

analyst
#15

And the investment-

Adam Greenlee

executive
#16

When we consider investments, a lot like how we are preparing for the Trivium acquisition close date in mid-2027, nothing has truly been prepared for us to share at this point about how big those investments will be. I think we are taking a very deep dive look at all three segments that we have today and making sure that we prepare them for a successful transition next year. As we move from our current reporting structure to more of an MCC and Dispensing Solutions reporting structure, we are going to want to make sure those businesses are ready and able to stand on their two feet in very secure footing.

George Staphos

analyst
#17

All right. Thank you very much, Adam. I'll turn it over.

Matt Roberts

analyst
#18

Hi Adam, Shawn, and Alex—good morning. Regarding the pharma growth, I believe you mentioned that prescription pharma dispensing came in above expectations. Last quarter, I think you said it was weighted more toward 4Q. Given that 3Q strength, was there any earlier ramp or inventory timing, or do you still expect it to continue at a similar pace in 4Q in 2027?

Adam Greenlee

executive
#19

Sure. Look, we're excited—we've been discussing our healthcare pharma growth for a while now, and it's among the fastest-growing areas of our portfolio. We expected this growth later in the year; to be fair, it's probably a combination, Matt. We're likely shipping a bit ahead of our initial expectations. But the strength we're seeing in Q4 aligns very well with what we just delivered in Q3. So we're really excited about the progress we've made there. It's great to have those products commercialized and in the market. Again, this is definitely an important, rapidly expanding piece of our overall healthcare business that we've been talking about—that, this year, we'll be in that $250 million total revenue range for Silgan, and we anticipate solid growth again next year as well.

Matt Roberts

analyst
#20

Thanks, Adam. That means a lot. We've already gone over the Dispensing Solutions margin somewhat, and I realize you likely won't give much of a 2027 outlook, but perhaps considering those cost recoveries that affected margin this year, considering the drag you just had in Closures, but the growth you're seeing in Dispensing, think about just the proposed Dispensing Solutions business. Once you get those cost recoveries, you just discussed pharma growth and a Brazil recovery, how do you see just Dispensing Solutions ramping in 2027 or over a longer horizon? Or to put it another way, leaving aside some of those one-time Closures impacts, how has just the Dispensing performed on an organic or going-forward basis? Appreciate you taking the question.

Adam Greenlee

executive
#21

Yeah, so first off, we aren't giving guidance for 2027, though I think it's fair to speak in general terms about how these particular products look over the longer term. Perhaps I'll return to what's in our portfolio right now. Yes, consumers have been under pressure in 2026 in some markets, but our view and our expectations regarding long-term volume or the profile of any of our segments haven't shifted at all. As you shift the Dispensing and Specialty Closures segment toward becoming more of a Dispensing Solutions segment, Matt, my expectation is that you'll see a greater share of the volume from fragrance dispensing and beauty, along with more volume from healthcare pharma, actually flowing down into that segment's bottom line, since we're transferring the steadier portion of the portfolio in food and beverage over to the Silgan MCC business. To reiterate, our perspective on individual markets remains the same, yet Dispensing Solutions ought to post an accelerated growth rate, since after completing that transition it will concentrate more on end markets that are expanding faster and carry better margins. All right. Thanks.

Jeff Zekauskas

analyst
#22

Thank you so much. You mentioned you expected free cash flow to increase in 2027; broadly speaking, is that growth minimal or significant? How would you put a number on it?

Shawn Fabry

executive
#23

Hi, Jeff, Shawn here. Yeah.

Jeff Zekauskas

analyst
#24

Hello.

Shawn Fabry

executive
#25

Please, go ahead. Yes. We anticipate free cash flow growth in 2027, though at this stage we aren't providing specific guidance on it. Still, I'd view that as something that will depend on volume growth during the year, so for now I'd put out there a modest level of free cash flow growth of some kind; we always run initiatives focused on working capital. That won't be any different in 2027; and our attention is always on every aspect of free cash flow, the CapEx equation included.

Jeff Zekauskas

analyst
#26

Polypropylene and polyethylene prices are moving up. Will that hit you more in Q4 or Q1, given that you mentioned recovering margins somewhat?

Adam Greenlee

executive
#27

Yeah. I think when you look across the portfolio, we've had a very long history of disciplined pass-through, certainly on the raw material side, which is contractual in nature, right? I think in our food and beverage closures and our Custom Containers business, pass-throughs are pretty tight, and we handle that very effectively. I think the newest part of the portfolio, in our Dispensing Solutions portion, has a slightly longer lag. So if I were just going to give you a round number, Jeff, it's probably more on a quarterly basis.

Jeff Zekauskas

analyst
#28

Yeah.

Adam Greenlee

executive
#29

Recovery is going to happen over a stretch of time. Resin in particular will be recovered in Q4, along with the other inflation we've been dealing with. And then, on those items with longer lags, a portion of that for our Dispensing Solutions will spill over into Q1, just as you'd expect. And our pass-throughs track resin cost changes quite closely.

Jeff Zekauskas

analyst
#30

Great. Thanks a lot.

Bryan Burgmeier

analyst
#31

Hello. Good morning. Bryan Burgmeier here, filling in for Anthony. Appreciate you taking the question. In the press release, you talked about better price cost for Metal Containers during the quarter. I'm just wondering whether that ties to your formula pass-throughs or perhaps some underlying cost savings. And zooming out, from a high level, how has inflation affected Metal Containers this year, and how do your formulas offset that? Is there any additional catch-up going into 2027?

Adam Greenlee

executive
#32

Sure. Hey, Bryan. When we think specifically about Metal Containers, one thing that maybe doesn't get enough attention is how well all three of our businesses performed last year and the year before in carrying out our cost reduction initiative program, through which we removed $50 million of cost from our overall operating network. What you're seeing this year, especially in Metal Containers, is the payoff from those actions. We shut three facilities last year; that brings down the overall operating cost for our system; and for the first time in several years, we were able to plan for the fruit and vegetable pack, rather than the disruptive kind of situation we had been coping with for many years leading up to the resolution we reached last year. Having the ability to plan for the fruit and vegetable pack let us run our facilities far more efficiently. Those two factors, I think, are really what's driving a lower cost profile for our Metal Containers business, and we feel terrific about how sustainable that is. It demonstrates the power of our network. When we can plan volumes with our customers, we're incredibly efficient, and you see that flowing through to the bottom line. And again, for Metal Containers, the inflationary pass-throughs we have, obviously raw materials, steel, aluminum, those are very much on a real-time basis, so that hasn't changed at all. The other manufacturing costs and other cost pass-throughs typically operate on a bit of a lag basis. The 2026 experience will be passing through in 2027, as it has been really since the inception of that part of our portfolio.

Bryan Burgmeier

analyst
#33

Understood. I appreciate all of that context — it's extremely useful. So finally, and apologies if I overlooked it, could you give a high-level view of what caused the beat this quarter versus Silgan's projections? Thank you. I'll turn it over now.

Adam Greenlee

executive
#34

Yes. From our perspective, first of all, it was a strong quarter, and I'd call it a resilient one across every business we have. That's on an operating EBIT basis. Clearly, on the corporate line, we could adjust out certain costs incurred related to the announced transaction involving the acquisition of Trivium, so that gave a modest benefit. Shawn, would you like to cover interest?

Shawn Fabry

executive
#35

Yes, absolutely. Interest also came in better than we had anticipated for the quarter. As we entered the year, we noted that we would build in additional unknowns, and this is an area that has faced considerable headwinds. Consider the rising rate environment, along with our 1.4% notes that had to be redeemed during the first quarter. The team has performed very well on certain active global treasury initiatives, primarily centered on cash repatriation. As Adam just noted, we also did a very solid job handling our seasonal working capital requirements this year, thanks to the more stable footprint and the more normal volume cadence. Strong results on interest; we anticipate that carrying into the remainder of the year, and at this point we expect interest to be comparable year-over-year on a full-year basis.

Mike Roxland

analyst
#36

Hello, and good morning to all of you. I appreciate you taking my questions. Adam, you referred to putting actions in place to recover cost increases during Q3 and Q4. You pointed out specifically that in Dispensing and Specialty Closures, in cases where you lack contractual pass-throughs, you have implemented aggressive pricing actions. Could you remind us what percentage of Dispensing and Specialty Closures lacks contractual pass-throughs? And could you speak to any other steps you might be taking, whether in DSC or in your other businesses, to recover costs?

Adam Greenlee

executive
#37

Yes. That's a good question, Mike, and perhaps I should clarify something. The great majority of the business we have, certainly within our Dispensing and Specialty Closures segment, does carry contractual pass-throughs. Most of that relates to raw materials. I probably could have phrased it more clearly and said that in cases where we don't have contractual pass-through of other inflationary costs, that is where we've acted in the market, and that is where we've specifically pursued additional price increases and cost recovery efforts within this part of our portfolio; the same holds in the other parts of our portfolio. Metal Containers, certainly, is largely covered by our larger contractual pass-throughs, so no additional action really needs to be taken there. Custom Containers has done well at incorporating many of those inflationary pass-throughs into their contractual business as well. It really is only Dispensing where we have been discussing the absence of that language in our contract. We need to act in order to recover, and our teams did an outstanding job of going to the market, having those difficult conversations, and demonstrating the value we have delivered to our customers over a long period of time, and they were rewarded with the ability to pass through those inflationary costs.

Mike Roxland

analyst
#38

Understood. No, that's quite clear. Thanks for clarifying; so just one quick question then. Could you discuss your capacity to grow or to grow further in healthcare and pharma while simultaneously pursuing this transaction with AIP? Obviously, you're seeing notable traction with prescription pharma, up double digits as you mentioned in your North American Q3. But clearly getting this deal completed is also a priority. You mentioned, I believe earlier, a mid-2027 type target for closing the transaction; so could you pursue healthcare and pharma while doing this deal without the deal really acting as a distraction to your growth in pharma?

Adam Greenlee

executive
#39

Yeah. Maybe I'll begin, and everyone else, Shawn and Alex, please jump in here. But maybe just start with the notion of, again, going back to Silgan Holdings and what we are. We're a holding company here at our offices in Norwalk, and we have specialists who run each of our operating companies out in the field; so just that very nature, Mike, lets us keep focusing on the right strategic direction for the company here out of this office with our team in Connecticut. So I actually think, in fairness, it's no change whatsoever, even with the announced Trivium acquisition, to what we're doing from an M&A perspective out in the market and what we're considering and actually our ability to execute. I think it might actually be better. As you recall, the Trivium acquisition is designed to be leverage neutral to Silgan, and that's a really important part of that discussion. As we think about reallocating the balance sheet, our Dispensing Solutions business will have, I think as we talked last week, leverage at inception of about 1.8x ; we're going to be looking to have the ability to deploy capital just as we have been in the past. So I don't view it any differently than where we were prior to the announcement last week, and just excited about the growth opportunities that still sit in front of us across the portfolio.

Mike Roxland

analyst
#40

Understood. Thank you so much.

Hillary Cacanando

analyst
#41

Hello, and thanks. Even with the consumer environment softer, fragrance keeps expanding at a mid-single-digit pace. What do you see in that market that makes you confident growth can carry on through 2027? How much of that is market growth versus share gains or new business wins on your side?

Adam Greenlee

executive
#42

That's a good question. I'd say it's a central piece of our strategy, especially in high-end fragrance. Right, we simply keep executing. Our team is performing really well; we keep bringing in new business, and what matters is that when we talk about winning new business, we mean winning new product launches. We truly aren't competing on anything sitting on the store shelf. We're capturing, I believe the phrase we've used before is, a disproportionate amount of the new product launches. Perhaps there's a launch happening today where we take seven of the eight sprayers within a family of products that our customers are bringing to market, and that is lifting our market share. That's the way we succeed in the market — our design, our capabilities, through innovation and partnerships with our customers, are producing those opportunities. For 2027, our visibility is really strong because, frankly speaking, all of those conversations took place in earlier years. We have product launch schedules and quite clear visibility into demand. We're currently discussing new product launches for 2028 and 2029. A lot of those launches will call for investment, which falls within our normal CapEx requirements for the business. Yet those investments for 2027 are already done, and we expect to execute once more — we'll say mid-single-digit growth is the expectation over the long term, but that certainly holds for 2027 for our high-end fragrance products too.

Hillary Cacanando

analyst
#43

Understood. Thanks — that's quite useful. Regarding the added investment before the Trivium deal closes, ought we mainly to view it as an expense hitting earnings, as extra capital spending, or possibly as both?

Adam Greenlee

executive
#44

My view is that it will be additional capital. When we examine it, we have — call them fairly small outlays — in products and operating facilities, plus in people and teams going forward. There are all sorts of items we're reviewing simply to guarantee we're fully prepared and capable of launching very successfully once the Trivium transaction is completed.

Hillary Cacanando

analyst
#45

Understood. Excellent. Many thanks.

Arun Viswanathan

analyst
#46

Good. Appreciate you taking the question. Trust you're all doing well. I'd like to go a bit deeper on volumes. More specifically, in DSC, could you perhaps help us get a handle on things — fragrance and prescription pharma were really strong. What share of that segment does that represent, and perhaps on a percentage of sales or EBITDA basis? And then, assuming it's under half, which I believe is the case, what's your view on the weaker portions of the business? Do you expect those might turn positive, or is inflation really the main driver? I suppose, what are your customers telling you regarding promotion there?

Alex Hutter

executive
#47

Yes, so you're correct, it's under half for fragrance and beauty. It's nearer a third, or slightly above that. Healthcare, as Adam mentioned, represents roughly a $250 million business for us.

Adam Greenlee

executive
#48

I think once we pull all of that together, you're right. What we saw in fragrance and what we saw in healthcare got offset mostly by the softness in food and beverage. As we look toward Q4, we expect a similar picture, with volumes comparable to the prior year. Fragrance will grow, prescription pharma will grow, and I think you'll still be facing that challenged consumer in our food and beverage market.

Alex Hutter

executive
#49

One more point I’d make, Arun: a reason the deal was structured with Silgan MCC and Dispensing Solutions split apart is so that the growth on the dispensing side can be shown to you more clearly. The portion of the portfolio you asked about — fragrance and beauty, personal care — makes up roughly half of the end market for Dispensing Solutions, and healthcare accounts for closer to 10% of Dispensing Solutions’ end markets. Some of these masking effects we’re discussing right now will obviously become a bit less clear as those areas become more concentrated in the growth end markets at Silgan DS.

Arun Viswanathan

analyst
#50

Thanks for that. I suppose, as you head into 2027, perhaps easier comps are coming your way. I guess, does that offer some degree of comfort that you might deliver, say, low single digit growth in Dispensing and Specialty Closures? Also, as I said earlier, what are your customers telling you on the food and beverage side? Is it mostly deflation that will drive some volume recovery, or are they ramping up promotions or doing anything strategic to improve their own volume outlook? Thanks.

Adam Greenlee

executive
#51

Sure. I think, just like Silgan's outlook on the segments, from a long-term perspective nothing has changed, from a volume expectation perspective. Long term, we do think we have got kind of mid-single digit growth in our fragrance and beauty, probably closer to high single digit growth in our healthcare pharma business. Food and beverage, we have always said, is kind of low single digit. You are right, that that has not happened in 2026. But from a long-term perspective, nothing has really changed. Arun, I think those conversations with our customers, we are having those all the time. I think at this point we are getting a bit of varied feedback. Some are continuing to use promotional activity to offset the price point in the market, and in some of those areas we are seeing success. As we talked about, soup in particular, some are actually going to have to go back to market and are taking price to recover additional inflation that they have incurred. So, across all of our customers, it is not a one answer fits all, and we are working with them trying to help them be successful in the market. Again, while not giving specific guidance, I think 2027, we think that the pockets of strength that we have will continue to deliver, and we think that the stable parts of our portfolio should be more stable in 2027.

Arun Viswanathan

analyst
#52

Appreciate it. If I can fit in one last question. You said you're capturing business at a disproportionate rate across a handful of those verticals. What's behind that? Is innovation the main driver? Does the customer lead it? Or is it price, service, or reliability of supply? Which factors are producing that outsized share gain? Thank you.

Adam Greenlee

executive
#53

Certainly. This is a topic we've discussed for a number of years now. Innovation is genuinely where it begins. Our teams are intensely focused on what makes each customer's needs unique, and I believe we outperform everyone in the market at satisfying those distinct needs, grasping what our customers require, and assisting them in resolving their challenges. So those efforts are paying off for us. Especially within the high-end fragrance market, that is what enables us to capture a disproportionate share of new product launches. We take real pride in that. I think the market had been looking for a player to come in at a certain point, fill that gap, and serve their needs. I believe we're witnessing a quite similar response at present in our prescription pharma business. We are unquestionably global leaders and experts in dispensing technology and differentiated Dispensing Solutions. The marketplace is rewarding those.

Anojja Shah

analyst
#54

Good morning, everyone. First off, could you remind us of the anniversary date for the business exit taking place in Custom Containers? Once that's completed, do you expect that segment to be at a steady state, or are additional growth and margin initiatives in the works? I'm simply trying to understand what steady state performance for that business could look like within the remaining Silgan Dispensing business.

Adam Greenlee

executive
#55

Certainly. As we mentioned a bit earlier, we've removed a significant amount of cost from our Custom Containers segment; that work wrapped up in Q4 of last year. So we're now lapping that for the last time in Q4. Heading into 2027, you'll see a steady state roughly comparable to prior years; so I think that opens a broader discussion about Custom Containers and how we see that business going forward. It's been a long journey of improving that business, and we've cut costs; we've enhanced margins. We've narrowed the business onto a very clear subset of the rigid blow molding business, and they're performing really well and doing a great job. I think the business is now positioned for growth going forward, and I think we're close to turning the corner, where expectations for growth in Custom Containers will shift in the future. That's not in Q4. That's not in Q1. For us, that is a longer-term vision. But we believe the unique model they have for serving their customers in the markets they've continued to win in offers the opportunity for continued growth. We'll pursue that at the margin rates we've been enjoying and worked really hard to reach, and we think that's a great part of our Dispensing Solutions portfolio on a go-forward basis.

Anojja Shah

analyst
#56

Great, and thanks for taking the question. I'd like to circle back to those fragrance product launches. I realize we've covered this a few times already, but I want to dig a little deeper. Because it's going to sit within the new dispensing business, could you possibly share any additional detail about what winning a fragrance launch means financially? Particularly since it sounds like you have multi-year visibility there. Ideally, perhaps what a launch win translates into for EBIT contribution, or even volume growth, over the coming few years. Thanks.

Adam Greenlee

executive
#57

Sure. I believe some of those discussions can happen as we move forward. What I would say is this: given that visibility, the mid-single-digit volume growth we project ahead for fragrance specifically — fragrance and beauty — I think captures all of those new product launches we've discussed. We enjoyed a tremendous stretch of double-digit growth on a quarterly basis for, I believe, five or six consecutive quarters. Looking ahead, I think that growth remains right in front of us in these markets, thanks to the innovation and the products we bring to market.

Anojja Shah

analyst
#58

Great, thanks.

Dan Rizzo

analyst
#59

Hi, everyone, and I appreciate you squeezing me in. Regarding the prescription pharma dispensing business — I realize it's expanding nicely. I wanted to ask, have you ever shared what share of sales that segment represents? And second, does that differ from your other operations? Is it, say, a multi-year affair to secure some kind of government license or similar, such that several years pass before you truly see anything start to come out of it?

Adam Greenlee

executive
#60

Sure. Hi, Dan. So, this is a portion of our portfolio that's expanding quickly. As we've mentioned, it's approximately a $250 million business overall for us at Silgan. Mostly, it sits within what will eventually become the Dispensing Solutions segment. These products are largely regulated, meaning they need considerable development work and considerable regulatory scrutiny. The pipelines here run three to five years. Personally, the encouraging part is that the items we discussed in Q3, along with what will affect Q4 and beyond, have been in development for quite a while; we're referring to drug master files. We're referring to all of that. Once more, I believe the market wanted someone to step in, exactly as we did with our high-end fragrance business. We aren't competing on price, to be completely clear on that point. This is about innovation. It's about addressing a customer's specific requirements and fueling their expansion through innovative and differentiated technologies.

Dan Rizzo

analyst
#61

Do you track a win-loss ratio? My assumption is that among the products you handle on the drug master file, certain ones—not due to anything on your side, but because the customer's product never launches or for some other reason—I was curious whether that is something that impacts you folks periodically too.

Adam Greenlee

executive
#62

Of course. Not every item reaches a commercialized stage with the customer as they transition away from drug trials or similar efforts. Still, from our standpoint, the key point is that the technology we offer isn’t tied to any single drug or any single molecule, so to speak. We believe our dispensing technology has a wide range of applications, and once again, it comes down to working alongside our customers to identify the most suitable use cases for those technologies.

Dan Rizzo

analyst
#63

Thanks so much.

George Staphos

analyst
#64

Hello, everyone, and thanks for taking the follow-up. I have two questions. First, when you consider how your customers are assessing their pricing and promotional strategies — and you touched on this a bit earlier in the quarter, or rather on this call — are you perhaps seeing the tip of the spear here in soup, where customers will understandably try to pass through the inflation they have felt over the last year or so? I know you said it isn't a one-size-fits-all item, but what are you seeing on the margins? Is this perhaps something your customers will be doing that you'll have to deal with over the next 12 months? Recognizing that you have a lot to work through with Trivium, in a good way, how would you size what's left in the metal markets on self-make as potentially a longer-term growth opportunity several years out? Thank you, and good luck in the quarter.

Adam Greenlee

executive
#65

Sure. Thank you, George. I think, once more, many discussions with customers are aimed at making sure everyone grasps how inflation has affected not just their operations but also the items we provide. You're correct that we're taking time to learn about their pricing approaches, their promotional approaches, and how they're going to market. Things are mixed at the moment. I don't believe I can offer a superior response to that. Certain customers—and definitely certain products—are still concentrating on promotional efforts, and that is fueling volume growth. We continue to see that plainly in some sections of our portfolio, and we've observed others, especially in soup, as we talked about, where they have chosen—or decided—that they must recoup part of the inflation they encountered in 2026, and they will bring that price to market. I want to be quite cautious and state that we don't believe this applies uniformly to every one of our customers. We truly don't; but I think it's the start of a dialogue, simply ensuring everyone understands what their plans are for 2027 and beyond. Regarding Trivium, I think the single point I'd make, George, is that private label involves a consumer who is under pressure. Trade down is definitely occurring. Private label is doing extremely well, especially in the food can business and in the U.S. You have a big self-manufacturer that leads the private label business. So they've done a fantastic job serving consumers and supplying low-cost nutrition and low-cost items in those markets. Once again, they possess a very robust business model that they've kept executing. Really there is one big one in North America, and they've done a truly good job with their business.

George Staphos

analyst
#66

All right. Thank you. I will turn it over. Good luck in the quarter.

Adam Greenlee

executive
#67

Thanks, Jess. We really appreciate everyone taking an interest in the company, and we're looking forward to talking through our full year and fourth quarter results once the year has begun.

Operator

operator
#68

Thanks. That wraps up today's call, everyone, and we appreciate you joining us. You're free to disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Silgan Holdings Inc. transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Silgan Holdings Inc. earnings transcripts and 131,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Silgan Holdings Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.